Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 262

1.

The Role of Xpert MTB/RIF Ultra in Diagnosing Pulmonary Tuberculosis in Children.

Schaaf HS, Marais BJ.

Am J Respir Crit Care Med. 2019 Aug 6. doi: 10.1164/rccm.201907-1492ED. [Epub ahead of print] No abstract available.

PMID:
31386819
2.

Management of patients with multidrug-resistant tuberculosis.

Lange C, Aarnoutse RE, Alffenaar JWC, Bothamley G, Brinkmann F, Costa J, Chesov D, van Crevel R, Dedicoat M, Dominguez J, Duarte R, Grobbel HP, Günther G, Guglielmetti L, Heyckendorf J, Kay AW, Kirakosyan O, Kirk O, Koczulla RA, Kudriashov GG, Kuksa L, van Leth F, Magis-Escurra C, Mandalakas AM, Molina-Moya B, Peloquin CA, Reimann M, Rumetshofer R, Schaaf HS, Schön T, Tiberi S, Valda J, Yablonskii PK, Dheda K.

Int J Tuberc Lung Dis. 2019 Jun 1;23(6):645-662. doi: 10.5588/ijtld.18.0622.

PMID:
31315696
3.

Tuberculosis transmission in a hospitalised neonate: Need for optimised tuberculosis screening of pregnant and postpartum women.

Zenhäusern J, Bekker A, Wates MA, Schaaf HS, Dramowski A.

S Afr Med J. 2019 Apr 29;109(5):310-313. doi: 10.7196/SAMJ.2019.v109i5.13789.

PMID:
31131796
4.

Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies.

Garcia-Prats AJ, Schaaf HS, Draper HR, Garcia-Cremades M, Winckler J, Wiesner L, Hesseling AC, Savic RM.

PLoS Med. 2019 Apr 30;16(4):e1002789. doi: 10.1371/journal.pmed.1002789. eCollection 2019 Apr.

5.

Culture-confirmed Tuberculosis in South African Infants Younger Than 3 Months of Age: Clinical Presentation and Management of Respiratory Complications.

Frigati L, Bekker A, Stroebele S, Goussard P, Schaaf HS.

Pediatr Infect Dis J. 2019 Apr;38(4):351-354. doi: 10.1097/INF.0000000000002163.

PMID:
30882723
6.

Treatment Outcomes in Global Systematic Review and Patient Meta-Analysis of Children with Extensively Drug-Resistant Tuberculosis.

Osman M, Harausz EP, Garcia-Prats AJ, Schaaf HS, Moore BK, Hicks RM, Achar J, Amanullah F, Barry P, Becerra M, Chiotan DI, Drobac PC, Flood J, Furin J, Gegia M, Isaakidis P, Mariandyshev A, Ozere I, Shah NS, Skrahina A, Yablokova E, Seddon JA, Hesseling AC; Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in MDR TB.

Emerg Infect Dis. 2019 Mar;25(3):441-450. doi: 10.3201/eid2503.180852.

7.

Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure.

Garcia-Prats AJ, Purchase SE, Osman M, Draper HR, Schaaf HS, Wiesner L, Denti P, Hesseling AC.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e01865-18. doi: 10.1128/AAC.01865-18. Print 2019 Apr.

PMID:
30670421
8.

Diagnosis and Management of Multidrug-Resistant Tuberculosis in Children: A Practical Approach.

Schaaf HS.

Indian J Pediatr. 2019 Aug;86(8):717-724. doi: 10.1007/s12098-018-02846-8. Epub 2019 Jan 17.

PMID:
30656560
9.

Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP).

Seddon JA, Garcia-Prats AJ, Purchase SE, Osman M, Demers AM, Hoddinott G, Crook AM, Owen-Powell E, Thomason MJ, Turkova A, Gibb DM, Fairlie L, Martinson N, Schaaf HS, Hesseling AC.

Trials. 2018 Dec 20;19(1):693. doi: 10.1186/s13063-018-3070-0.

10.

Global shortages of BCG vaccine and tuberculous meningitis in children.

du Preez K, Seddon JA, Schaaf HS, Hesseling AC, Starke JR, Osman M, Lombard CJ, Solomons R.

Lancet Glob Health. 2019 Jan;7(1):e28-e29. doi: 10.1016/S2214-109X(18)30474-1. No abstract available.

11.

Acceptability of a Novel Levofloxacin Dispersible Tablet Formulation in Young Children Exposed to Multidrug-resistant Tuberculosis.

Purchase SE, Garcia-Prats AJ, De Koker P, Draper HR, Osman M, Seddon JA, Schaaf HS, Hesseling AC.

Pediatr Infect Dis J. 2019 Jun;38(6):608-610. doi: 10.1097/INF.0000000000002268.

PMID:
30550511
12.

Specimen Pooling as a Diagnostic Strategy for Microbiologic Confirmation in Children with Intrathoracic Tuberculosis.

Walters E, van der Zalm MM, Demers AM, Whitelaw A, Palmer M, Bosch C, Draper HR, Schaaf HS, Goussard P, Lombard CJ, Gie RP, Hesseling AC.

Pediatr Infect Dis J. 2019 Jun;38(6):e128-e131. doi: 10.1097/INF.0000000000002240.

PMID:
30418355
13.

Child and adult spinal tuberculosis at tertiary hospitals in the Western Cape, South Africa: 4-year burden and trend.

Mann TN, Schaaf HS, Dunn RN, Dix-Peek S, du Preez K, Lamberts RP, du Toit J, Davis JH.

Epidemiol Infect. 2018 Dec;146(16):2107-2115. doi: 10.1017/S0950268818002649. Epub 2018 Sep 28.

14.

Cost-effectiveness of home-based vs. in-hospital treatment of paediatric tuberculous meningitis.

van Elsland SL, van Dongen SI, Bosmans JE, Schaaf HS, van Toorn R, van Furth AM.

Int J Tuberc Lung Dis. 2018 Oct 1;22(10):1188-1195. doi: 10.5588/ijtld.18.0236.

PMID:
30236187
15.

Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis.

Seddon JA, Schaaf HS, Marais BJ, McKenna L, Garcia-Prats AJ, Hesseling AC, Hughes J, Howell P, Detjen A, Amanullah F, Singh U, Master I, Perez-Velez CM, Misra N, Becerra MC, Furin JJ.

Lancet Respir Med. 2018 Sep;6(9):662-664. doi: 10.1016/S2213-2600(18)30329-1. No abstract available.

16.

Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.

Harausz EP, Garcia-Prats AJ, Law S, Schaaf HS, Kredo T, Seddon JA, Menzies D, Turkova A, Achar J, Amanullah F, Barry P, Becerra M, Chan ED, Chan PC, Ioana Chiotan D, Crossa A, Drobac PC, Fairlie L, Falzon D, Flood J, Gegia M, Hicks RM, Isaakidis P, Kadri SM, Kampmann B, Madhi SA, Marais E, Mariandyshev A, Méndez-Echevarría A, Moore BK, Nargiza P, Ozere I, Padayatchi N, Ur-Rehman S, Rybak N, Santiago-Garcia B, Shah NS, Sharma S, Shim TS, Skrahina A, Soriano-Arandes A, van den Boom M, van der Werf MJ, van der Werf TS, Williams B, Yablokova E, Yim JJ, Furin J, Hesseling AC; Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in MDR-TB.

PLoS Med. 2018 Jul 11;15(7):e1002591. doi: 10.1371/journal.pmed.1002591. eCollection 2018 Jul.

17.

Clinical and Cardiac Safety of Long-term Levofloxacin in Children Treated for Multidrug-resistant Tuberculosis.

Garcia-Prats AJ, Draper HR, Finlayson H, Winckler J, Burger A, Fourie B, Thee S, Hesseling AC, Schaaf HS.

Clin Infect Dis. 2018 Nov 13;67(11):1777-1780. doi: 10.1093/cid/ciy416.

PMID:
29788331
18.

Conducting efficacy trials in children with MDR-TB: what is the rationale and how should they be done?

Seddon JA, Weld ED, Schaaf HS, Garcia-Prats AJ, Kim S, Hesseling AC.

Int J Tuberc Lung Dis. 2018 May 1;22(5):24-33. doi: 10.5588/ijtld.17.0359.

19.

Current status of pharmacokinetic and safety studies of multidrug-resistant tuberculosis treatment in children.

Garcia-Prats AJ, Svensson EM, Weld ED, Schaaf HS, Hesseling AC.

Int J Tuberc Lung Dis. 2018 May 1;22(5):15-23. doi: 10.5588/ijtld.17.0355. Review.

PMID:
29665949
20.

Timing of HIV diagnosis in children with tuberculosis managed at a referral hospital in Cape Town, South Africa.

Byamungu LN, du Preez K, Walters E, Nachega JB, Schaaf HS.

Int J Tuberc Lung Dis. 2018 May 1;22(5):488-495. doi: 10.5588/ijtld.17.0613.

PMID:
29663952
21.

Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.

Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, Bang D, Bastos M, Benedetti A, Bonnet M, Cattamanchi A, Cegielski P, Chien JY, Cox H, Dedicoat M, Erkens C, Escalante P, Falzon D, Garcia-Prats AJ, Gegia M, Gillespie SH, Glynn JR, Goldberg S, Griffith D, Jacobson KR, Johnston JC, Jones-López EC, Khan A, Koh WJ, Kritski A, Lan ZY, Lee JH, Li PZ, Maciel EL, Galliez RM, Merle CSC, Munang M, Narendran G, Nguyen VN, Nunn A, Ohkado A, Park JS, Phillips PPJ, Ponnuraja C, Reves R, Romanowski K, Seung K, Schaaf HS, Skrahina A, Soolingen DV, Tabarsi P, Trajman A, Trieu L, Banurekha VV, Viiklepp P, Wang JY, Yoshiyama T, Menzies D.

Lancet Respir Med. 2018 Apr;6(4):265-275. doi: 10.1016/S2213-2600(18)30078-X. Erratum in: Lancet Respir Med. 2018 Apr 18;:.

PMID:
29595509
22.

Complementary surveillance strategies are needed to better characterise the epidemiology, care pathways and treatment outcomes of tuberculosis in children.

du Preez K, Schaaf HS, Dunbar R, Walters E, Swartz A, Solomons R, Hesseling AC.

BMC Public Health. 2018 Mar 23;18(1):397. doi: 10.1186/s12889-018-5252-9.

23.

Effect of Coadministration of Lidocaine on the Pain and Pharmacokinetics of Intramuscular Amikacin in Children With Multidrug-Resistant Tuberculosis: A Randomized Crossover Trial.

Garcia-Prats AJ, Rose PC, Draper HR, Seddon JA, Norman J, McIlleron HM, Hesseling AC, Schaaf HS.

Pediatr Infect Dis J. 2018 Dec;37(12):1199-1203. doi: 10.1097/INF.0000000000001983.

24.

Adolescents and young adults: a neglected population group for tuberculosis surveillance.

García-Basteiro AL, Schaaf HS, Diel R, Migliori GB.

Eur Respir J. 2018 Feb 21;51(2). pii: 1800176. doi: 10.1183/13993003.00176-2018. Print 2018 Feb. No abstract available.

25.

Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children.

Schaaf HS, Garcia-Prats AJ, McKenna L, Seddon JA.

Expert Rev Clin Pharmacol. 2018 Mar;11(3):233-244. doi: 10.1080/17512433.2018.1421067. Epub 2017 Dec 27. Review.

26.

Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.

Denti P, Garcia-Prats AJ, Draper HR, Wiesner L, Winckler J, Thee S, Dooley KE, Savic RM, McIlleron HM, Schaaf HS, Hesseling AC.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01521-17. doi: 10.1128/AAC.01521-17. Print 2018 Feb.

27.

Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.

van der Laan LE, Garcia-Prats AJ, Schaaf HS, Tikiso T, Wiesner L, de Kock M, Winckler J, Norman J, McIlleron H, Denti P, Hesseling AC.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e00420-17. doi: 10.1128/AAC.00420-17. Print 2018 Feb.

28.

Correction to: The impact of drug resistance on the risk of tuberculosis infection and disease in child household contacts: a cross sectional study.

Golla V, Snow K, Mandalakas AM, Schaaf HS, Du Preez K, Hesseling AC, Seddon JA.

BMC Infect Dis. 2017 Nov 7;17(1):713. doi: 10.1186/s12879-017-2806-x.

29.

Tuberculous Pericardial Effusions in Children.

Obihara NJ, Walters E, Lawrenson J, Garcia-Prats AJ, Hesseling AC, Schaaf HS.

J Pediatric Infect Dis Soc. 2018 Dec 3;7(4):346-349. doi: 10.1093/jpids/pix087.

PMID:
29096017
30.

The impact of drug resistance on the risk of tuberculosis infection and disease in child household contacts: a cross sectional study.

Golla V, Snow K, Mandalakas AM, Schaaf HS, Du Preez K, Hesseling AC, Seddon JA.

BMC Infect Dis. 2017 Aug 29;17(1):593. doi: 10.1186/s12879-017-2668-2. Erratum in: BMC Infect Dis. 2017 Nov 7;17(1):713.

31.

Drug-resistant tuberculosis and advances in the treatment of childhood tuberculosis.

Seddon JA, Schaaf HS.

Pneumonia (Nathan). 2016 Nov 24;8:20. doi: 10.1186/s41479-016-0019-5. eCollection 2016. Review.

32.

Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis.

Rabie H, Decloedt EH, Garcia-Prats AJ, Cotton MF, Frigati L, Lallemant M, Hesseling A, Schaaf HS.

Expert Opin Pharmacother. 2017 Apr;18(6):589-598. doi: 10.1080/14656566.2017.1309023. Epub 2017 Mar 27. Review.

PMID:
28346018
33.

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.

Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR Jr, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM.

Lancet Respir Med. 2017 Mar 15. pii: S2213-2600(17)30079-6. doi: 10.1016/S2213-2600(17)30079-6. [Epub ahead of print] Review.

PMID:
28344011
34.

Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.

Jaganath D, Schaaf HS, Donald PR.

J Antimicrob Chemother. 2017 Jul 1;72(7):1848-1857. doi: 10.1093/jac/dkx051. Review.

35.

Xpert MTB/RIF on Stool Is Useful for the Rapid Diagnosis of Tuberculosis in Young Children With Severe Pulmonary Disease.

Walters E, van der Zalm MM, Palmer M, Bosch C, Demers AM, Draper H, Goussard P, Schaaf HS, Friedrich SO, Whitelaw A, Warren R, Gie RP, Hesseling AC.

Pediatr Infect Dis J. 2017 Sep;36(9):837-843. doi: 10.1097/INF.0000000000001563.

36.

Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunities.

McAnaw SE, Hesseling AC, Seddon JA, Dooley KE, Garcia-Prats AJ, Kim S, Jenkins HE, Schaaf HS, Sterling TR, Horsburgh CR.

Int J Infect Dis. 2017 Mar;56:194-199. doi: 10.1016/j.ijid.2016.11.423. Epub 2016 Dec 9. Review.

37.

New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations.

Harausz EP, Garcia-Prats AJ, Seddon JA, Schaaf HS, Hesseling AC, Achar J, Bernheimer J, Cruz AT, D'Ambrosio L, Detjen A, Graham SM, Hughes J, Jonckheere S, Marais BJ, Migliori GB, McKenna L, Skrahina A, Tadolini M, Wilson P, Furin J; Sentinel Project on Pediatric Drug-Resistant Tuberculosis.

Am J Respir Crit Care Med. 2017 May 15;195(10):1300-1310. doi: 10.1164/rccm.201606-1227CI. Review.

38.

Tuberculosis Disease during Pregnancy and Treatment Outcomes in HIV-Infected and Uninfected Women at a Referral Hospital in Cape Town.

Bekker A, Schaaf HS, Draper HR, Kriel M, Hesseling AC.

PLoS One. 2016 Nov 3;11(11):e0164249. doi: 10.1371/journal.pone.0164249. eCollection 2016.

39.

Outcome of culture-confirmed isoniazid-resistant rifampicin-susceptible tuberculosis in children.

Garcia-Prats AJ, du Plessis L, Draper HR, Burger A, Seddon JA, Zimri K, Hesseling AC, Schaaf HS.

Int J Tuberc Lung Dis. 2016 Nov;20(11):1469-1476.

PMID:
27776587
40.

Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis.

Dheda K, Chang KC, Guglielmetti L, Furin J, Schaaf HS, Chesov D, Esmail A, Lange C.

Clin Microbiol Infect. 2017 Mar;23(3):131-140. doi: 10.1016/j.cmi.2016.10.008. Epub 2016 Oct 15. Review.

41.

The safety and tolerability of the second-line injectable antituberculosis drugs in children.

Garcia-Prats AJ, Schaaf HS, Hesseling AC.

Expert Opin Drug Saf. 2016 Nov;15(11):1491-1500. Epub 2016 Aug 22. Review.

PMID:
27548570
42.

Preventing the spread of multidrug-resistant tuberculosis and protecting contacts of infectious cases.

Fox GJ, Schaaf HS, Mandalakas A, Chiappini E, Zumla A, Marais BJ.

Clin Microbiol Infect. 2017 Mar;23(3):147-153. doi: 10.1016/j.cmi.2016.08.024. Epub 2016 Aug 31. Review.

43.

Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A.

Clin Infect Dis. 2016 Oct 1;63(7):853-67. doi: 10.1093/cid/ciw566.

44.

Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A.

Clin Infect Dis. 2016 Oct 1;63(7):e147-e195. doi: 10.1093/cid/ciw376. Epub 2016 Aug 10.

45.

Surveillance provides insight into epidemiology and spectrum of culture-confirmed mycobacterial disease in children.

Schaaf HS, Garcia-Prats AJ, du Preez K, Rautenbach C, Hesseling AC.

Int J Tuberc Lung Dis. 2016 Sep;20(9):1249-56. doi: 10.5588/ijtld.15.0051.

PMID:
27510254
46.

Adverse effects of oral second-line antituberculosis drugs in children.

Schaaf HS, Thee S, van der Laan L, Hesseling AC, Garcia-Prats AJ.

Expert Opin Drug Saf. 2016 Oct;15(10):1369-81. doi: 10.1080/14740338.2016.1216544. Epub 2016 Aug 5. Review.

PMID:
27458876
47.

Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges.

Tadolini M, Garcia-Prats AJ, D'Ambrosio L, Hewison C, Centis R, Schaaf HS, Marais BJ, Ferreira H, Caminero JA, Jonckheere S, Sinha A, Herboczek K, Khaidarkhanova Z, Hayrapetyan A, Khachatryan N, Urtkmelidze Ia, Loreti C, Esposito S, Matteelli A, Furin J, Varaine F, Migliori GB.

Eur Respir J. 2016 Sep;48(3):938-43. doi: 10.1183/13993003.00705-2016. Epub 2016 Jun 23. No abstract available.

48.

Probable Levofloxacin-associated Secondary Intracranial Hypertension in a Child With Multidrug-resistant Tuberculosis.

van der Laan LE, Schaaf HS, Solomons R, Willemse M, Mohamed N, Baboolal SO, Hesseling AC, van Toorn R, Garcia-Prats AJ.

Pediatr Infect Dis J. 2016 Jun;35(6):706-8. doi: 10.1097/INF.0000000000001137.

PMID:
26974890
49.

Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.

Bekker A, Schaaf HS, Draper HR, van der Laan L, Murray S, Wiesner L, Donald PR, McIlleron HM, Hesseling AC.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2171-9. doi: 10.1128/AAC.02600-15. Print 2016 Apr.

50.

Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis.

Fox GJ, Mitnick CD, Benedetti A, Chan ED, Becerra M, Chiang CY, Keshavjee S, Koh WJ, Shiraishi Y, Viiklepp P, Yim JJ, Pasvol G, Robert J, Shim TS, Shin SS, Menzies D; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB, Ahuja S, Ashkin D, Avendaño M, Banerjee R, Bauer M, Burgos M, Centis R, Cobelens F, Cox H, D'Ambrosio L, de Lange WCM, DeRiemer K, Enarson D, Falzon D, Flanagan K, Flood J, Gandhi N, Garcia-Garcia L, Granich RM, Hollm-Delgado MG, Holtz TH, Hopewell P, Iseman M, Jarlsberg LG, Kim HR, Lancaster J, Lange C, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Narita M, Nathanson E, Odendaal R, O'Riordan P, Pai M, Palmero D, Park SK, Pena J, Pérez-Guzmán C, Ponce-de-Leon A, Quelapio MID, Quy HT, Riekstina V, Royce S, Salim M, Schaaf HS, Seung KJ, Shah L, Shean K, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Sung SW, Tabarsi P, Tupasi TE, Vargas MH, van Altena R, van der Walt M, van der Werf TS, Westenhouse J, Yew WW.

Clin Infect Dis. 2016 Apr 1;62(7):887-895. doi: 10.1093/cid/ciw002. Epub 2016 Jan 12.

PMID:
26757804

Supplemental Content

Loading ...
Support Center